Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

Detalhes bibliográficos
Autor(a) principal: Coimbra, Susana
Data de Publicação: 2014
Outros Autores: Figueiredo, Américo, Santos-Silva, Alice
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/109389
https://doi.org/10.2147/CE.S33940
Resumo: Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.
id RCAP_32d5be2251b68aa6e08b8c876cd4956d
oai_identifier_str oai:estudogeral.uc.pt:10316/109389
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasisinterleukin-17interleukin-17 receptormonoclonal antibodyT helper 17 pathwayAdvances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.Dove Medical Press Ltd2014info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/109389http://hdl.handle.net/10316/109389https://doi.org/10.2147/CE.S33940eng1555-1741Coimbra, SusanaFigueiredo, AméricoSantos-Silva, Aliceinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-10-12T08:58:22Zoai:estudogeral.uc.pt:10316/109389Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:25:35.132172Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
title Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
spellingShingle Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
Coimbra, Susana
interleukin-17
interleukin-17 receptor
monoclonal antibody
T helper 17 pathway
title_short Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
title_full Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
title_fullStr Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
title_full_unstemmed Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
title_sort Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
author Coimbra, Susana
author_facet Coimbra, Susana
Figueiredo, Américo
Santos-Silva, Alice
author_role author
author2 Figueiredo, Américo
Santos-Silva, Alice
author2_role author
author
dc.contributor.author.fl_str_mv Coimbra, Susana
Figueiredo, Américo
Santos-Silva, Alice
dc.subject.por.fl_str_mv interleukin-17
interleukin-17 receptor
monoclonal antibody
T helper 17 pathway
topic interleukin-17
interleukin-17 receptor
monoclonal antibody
T helper 17 pathway
description Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/109389
http://hdl.handle.net/10316/109389
https://doi.org/10.2147/CE.S33940
url http://hdl.handle.net/10316/109389
https://doi.org/10.2147/CE.S33940
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1555-1741
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Dove Medical Press Ltd
publisher.none.fl_str_mv Dove Medical Press Ltd
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134138166411264

Registros relacionados